Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing

Liver Transplantation

Volumn 12, Issue 2, 2006, Pages 292-300

  Fukudo, Masahide ^a   Yano, Ikuko ^a   Masuda, Satohiro ^a   Katsura, Toshiya ^a   Ogura, Yasuhiro ^b   Oike, Fumitaka ^b   Takada, Yasutsugu ^b   Tanaka, Koichi ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN A; PHOSPHATASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT ATRESIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; NEPHROTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; POSTOPERATIVE PERIOD; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; PILOT PROJECTS; PROSPECTIVE STUDIES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 33244457426     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20609     Document Type: Article

References (22)

1. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002;360:1119-1125.
2. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986;11:107-132.
3. Frey FJ, Horber FF, Frey BM. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clin Pharmacol Ther 1988;43:55-62.
4. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999;67: 1133-1137.
5. Barone G, Chang CT, Choc MG Jr, Klein JB, Marsh CL, Meligeni JA, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation 1996;61:875-880.
6. Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 2000;39:117-125.
7. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr post-dose levels in stable liver transplant patients. Transplantation 1998;66:1621-1627.
8. 2). Transplantation 2002;73:953-959.
9. Yantorno SE, Varela EB, Raffa SR, Descalzi VI, Gomez Carretero ML, Pirola DA, et al. How common is delayed cyclosporine absorption following liver transplantation? Liver Transpl 2005;11:167-173.
10. Lück R, Böger J, Kuse E, Klempnauer J, Nashan B. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy. Liver Transpl 2004;10: 686-691.
11. Jörgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003;57:93-98.
12. Fukudo M, Yano I, Masuda S, Fukatsu S, Katsura T, Ogura Y, et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in patients of living-donor liver transplantation. Clin Pharmacol Ther 2005;78:168-181.
13. Tarantino A, Passerini P, Campise M, Bonizzoni E, Ceccarini F, Montagnino G, et al. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose? Transplantation 2004;78:675-680.
14. Beal SL, Sheiner LB, eds. NONMEM User's Guide. San Francisco: NONMEM Project Group, University of California at San Francisco, 1992.
15. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin RP, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-260.
16. Masuda S, Goto M, Kiuchi T, Uemoto S, Kodawara T, Saito H, et al. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl 2003; 9:1108-1113.
17. 0 monitoring in de novo liver transplantation. Transplantation 2004;77:1632-1638.
18. Fukudo M, Yano I, Fukatsu S, Saito H, Uemoto S, Kiuchi T, et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet 2003;42:1161-1178.
19. Caruso R, Perico N, Cattaneo D, Piccinini G, Bonazzola S, Remuzzi G, et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem 2001;47:1679-1687.
20. Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 2004;4:621-625.
21. Schädeli F, Marti HP, Frey FJ, Uehlinger DE. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet 2002;41:59-69.
22. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999:68:1356-1361.